Organon (OGN) Common Equity (2020 - 2026)

Organon (OGN) has reported Common Equity for 7 consecutive years, with $903.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Common Equity rose 66.61% year-over-year to $903.0 million; the TTM figure through Mar 2026 stood at $903.0 million (up 66.61% YoY), while the FY2025 annual figure was $752.0 million, up 59.32% from the prior year.
• Common Equity came in at $903.0 million for Q1 2026 at Organon, up from $752.0 million in the prior quarter.
• The five-year high for Common Equity was $906.0 million in Q3 2025, with the low at -$1.2 billion in Q1 2022.
• Average Common Equity over 5 years is -$76.6 million, with a median of $48.0 million recorded in 2024.
• Across the five-year window, Common Equity tumbled 126.47% in 2022 and soared 1029.17% in 2025, its largest moves.
• Year by year, Common Equity stood at -$892.0 million in 2022, then soared by 92.15% to -$70.0 million in 2023, then soared by 774.29% to $472.0 million in 2024, then jumped by 59.32% to $752.0 million in 2025, then climbed by 20.08% to $903.0 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $903.0 million, $752.0 million, and $906.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.